Lessons from UK historical cohort studies of lower respiratory tract infections - Authors' reply

Abstract

Competing Interests: SCD and ABC are co-senior authors. ABC reports multiple grants from the Australian National Health and Medical Research Council (NHMRC), and other fees to the institution from work relating to independent data monitoring committee membership of an unlicensed vaccine (GlaxoSmithKline), an unlicensed monoclonal antibody for RSV (AstraZeneca), and a COVID-19 vaccine (Moderna), outside the submitted work; and fees to the institution from work relating to unlicensed therapies for bronchiectasis (inhaled antibiotics from Zambon and a molecule from Boehringer Ingelheim). JLP reports investigator-initiated funding from GlaxoSmithKline for unrelated research. SCD reports investigator-initiated funding from GlaxoSmithKline for unrelated research, and further investigator initiated funding from AstraZeneca. MSM reports other grants from Children's Hospital Foundation. All other authors declare no competing interests.